Personalized treatment of alcohol dependence

Current Psychiatry Reports

Volumn 14, Issue 5, 2012, Pages 486-493

  Kranzler, Henry R ^a,b   McKay, James R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

5 HTTLPR; A118G; Adaptive protocol; Adaptive trial designs; Alcohol dependence; Asn40Asp; Genetic moderation; Nalmefene; Naltrexone; Ondansetron; OPRM1; Pharmacogenetics; Sertraline; Stepped care; Substance use; Treatment algorithm

Indexed keywords

FLUOXETINE; FLUVOXAMINE; MU OPIATE RECEPTOR; NALTREXONE; ONDANSETRON; PLACEBO; SEROTONIN TRANSPORTER; SERTRALINE;

ALCOHOLISM; ALGORITHM; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; COST CONTROL; DRUG DOSE COMPARISON; DRUG RESPONSE; ETHNIC DIFFERENCE; GENETIC RISK; GENETIC VARIABILITY; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MOTIVATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPIC VARIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL SUPPORT; TREATMENT DURATION; TREATMENT PLANNING;

ALCOHOL DETERRENTS; ALCOHOLISM; HUMANS; INDIVIDUALIZED MEDICINE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84870810872     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0296-5     Document Type: Review

References (65)

1. Evers K. Personalized medicine in psychiatry: ethical challenges and opportunities. Dialogues Clin Neurosci. 2009;11(4):427-34.
2. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301-4.
3. Damani SB, Topol EJ. The case for routine genotyping in dualantiplatelet therapy. J Am Coll Cardiol. 2010;56(2):109-11.
4. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13(4):368-73. (Pubitemid 351399826)
5. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28(8):1546-52. (Pubitemid 41070891)
6. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet. 2009;23(3):252-61.
7. Murphy SA, Oslin DW, Rush AJ, Zhu J. Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology. 2007;32 (2):257-62. (Pubitemid 46106932)
8. McKay J. Treating Substance Use Disorders with Adaptive Continuing Care. Washington: American Psychological Association Press; 2009.
9. Collins LM, Murphy SA, Bierman KL. A conceptual framework for adaptive preventive interventions. Prev Sci. 2004;5(3):185-96. (Pubitemid 39158492)
10. ALLHAT Collaborative Research Group. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002;288(23):2981-97.
11. Rakowski W, Lipkus IM, Clark MA, Rimer BK, Ehrich B, Lyna PR, et al. Reminder letter, tailored stepped-care, and self-choice comparison for repeat mammography. Am J Prev Med. 2003;25 (4):308-14. (Pubitemid 37346152)
12. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. NEngl JMed. 2006;354(12):1231-42.
13. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-52.
14. Gelernter J, Kranzler HR. Genetics of alcohol dependence. Hum Genet. 2009;126(1):91-9.
15. Edenberg HJ, Kranzler HR. The contribution of genetics to addiction therapy approaches. Pharmacol Ther. 2005;108(1):86-93. (Pubitemid 41377121)
16. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol. 1995;15(6):615-35. (Pubitemid 26019815)
17. Yu L. The mu opioid receptor: from molecular cloning to functional studies. Addict Biol. 1996;1(1):19-30. (Pubitemid 126683415)
18. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry. 1997;2 (6):490-4.
19. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83(3):262-8.
20. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28(12):1789-95. (Pubitemid 39665194)
21. van den Wildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets JH, et al. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res. 2007;31(1):1-10. (Pubitemid 46025359)
22. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069-77. (Pubitemid 47360852)
23. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda Jr R. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30(8):1288-96. (Pubitemid 44114679)
24. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811-28. (Pubitemid 38869838)
25. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005;8(2):267-80. (Pubitemid 40769268)
26. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10 (3):258-68. (Pubitemid 32879092)
27. Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol. 2005;40(3):227-33. (Pubitemid 40613837)
28. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O'Malley SS. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry. 2007;62(6):694-7. (Pubitemid 47314376)
29. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007;31(4):555-63. (Pubitemid 46434892)
30. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345(24):1734-9.
31. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DW, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-17. (Pubitemid 44794003)
32. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl). 2009;201(4):611-8.
33. Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, et al. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics. 2011;21(12):902-5.
34. Kranzler H, Armeli S, Covault J, Tennen H. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol. In press.
35. Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008;32(7):1159-66.
36. Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM. κ-opioid receptors are implicated in the increased potency of intraaccumbens nalmefene in ethanol-dependent rats. Neuropharmacology. 2011;61(1-2):35-42.
37. Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized doubleblind placebo-controlled multicenter study. Alcohol Clin Exp Res. 2007;31(7):1179-87. (Pubitemid 46934385)
38. Mitchell JM, Fields HL, White RL, Meadoff TM, Joslyn G, Rowbotham MC, et al. The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. J Clin Psychopharmacol. 2007;27(1):112-5.
39. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda Jr R, McGeary JE, et al. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res. 2008;32(1):58-66. (Pubitemid 350293891)
40. Chamorro A, Marcos M, Mirón-Canelo J, Pastor I, Gonzalez-Sarmiento R, Laso FJ. Association of μ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012;17(3):505-12.
41. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry. 1994;36(5):326-37. (Pubitemid 24288762)
42. Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des. 2010;16 (19):2126-35.
43. Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20 (9):1534-41. (Pubitemid 26428102)
44. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24(7):1041-9. (Pubitemid 30604324)
45. Chick J, Aschauer H, Hornik K. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend. 2004;74(1):61-70. (Pubitemid 38457054)
46. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;284(8):963-71. (Pubitemid 30659126)
47. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274 (5292):1527-31. (Pubitemid 26403928)
48. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66(6):2621-4. (Pubitemid 26159101)
49. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg B, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78(5):815-26.
50. Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry. 2007;62(4):327-31. (Pubitemid 47444277)
51. Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011;168(3):265-75.
52. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol. 2011;31(1):22-30.
53. Bischof G, Grothues JM, Reinhardt S, Meyer C, John U, Rumpf HJ. Evaluation of a telephone-based stepped care intervention for alcohol-related disorders: a randomized controlled trial. Drug Alcohol Depend. 2008;93(3):244-51.
54. McKay JR, Alterman AI, Cacciola JS, O'Brien CP, Koppenhaver JM, Shepard DS. Continuing care for cocaine dependence: comprehensive 2-year outcomes. J Consult Clin Psychol. 1999;67(3):420-7. (Pubitemid 29266512)
55. McKay JR, Lynch KG, Shepard DS, Pettinati HM. The effectiveness of telephone-based continuing care for alcohol and cocaine dependence: 24-month outcomes. Arch Gen Psychiatry. 2005;62(2):199-207. (Pubitemid 40189137)
56. McKay JR, Lynch KG, Shepard DS, Morgenstern J, Forman RF, Pettinati HM. Do patient characteristics and initial progress in treatment moderate the effectiveness of telephone-based continuing care for substance use disorders? Addiction. 2005;100(2):216-26. (Pubitemid 40255379)
57. McKay JR, Van Horn D, Oslin DW, Ivey M, Drapkin ML, Coviello DM, et al. Extended telephone-based continuing care for alcohol dependence: 24-month outcomes and subgroup analyses. Addiction. 2011;106(10):1760-9.
58. O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med. 2003;163 (14):1695-704. (Pubitemid 36898958)
59. Friedmann PD, Hendrickson JC, Gerstein DR, Zhang Z. The effect of matching comprehensive services to patients' needs on drug use improvement in addiction treatment. Addiction. 2004;99(8):962-72. (Pubitemid 39452808)
60. Brooner R, Kidorf M. Using behavioral reinforcement to improve methadone treatment participation. Sci Pract Perspect. 2002;1:38-46.
61. King VL, Stoller KB, Hayes M, Umbricht A, Currens M, Kidorf MS, et al. A multicenter randomized evaluation of methadone medical maintenance. Drug Alcohol Depend. 2002;65(2):137-48. (Pubitemid 34084897)
62. Kidorf M, Neufeld K, Brooner RK. Combining steppedcare approaches with behavioral reinforcement to motivate employment in opioid-dependent outpatients. Subst Use Misuse. 2004;39(13-14):2215-38.
63. Brooner RK, Kidorf MS, King VL, Stoller KB, Neufeld KJ, Kolodner K, et al. Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence. Drug Alcohol Depend. 2007;88 Suppl 2:S14-23. (Pubitemid 46528063)
64. Kakko J, Gronbladh L, Svanborg KD, von Wachenfeldt J, Ruck C, Rawlings B, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797-803. (Pubitemid 46808535)
65. Marlowe DB, Festinger DS, Arabia PL, Dugosh KL, Benasutti KM, Croft JR, et al. Adaptive Interventions in Drug Court: A Pilot Experiment. Crim Justice Rev. 2008;33(3):343-60.